Hunan Cancer Hospital

A multicenter, single-arm, open-label, phase Ib/II study conducted in China evaluated JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone (GCTB). The study, approved by ethics committees and registered at ClinicalTrials.gov (NCT04255576), involved 24 centers and administered JMT103 subcutaneously at 2 mg/kg every four weeks. Primary endpoints included histopathological or radiological objective tumor response (OTR), with secondary endpoints covering overall response rate (ORR), disease control rate (DCR), time to progression (TTP), and safety. Statistical analyses were performed using SAS software, with a sample size of 125 patients to ensure a 95% confidence interval for OTR.

SHR-A1921, an antibody-drug conjugate, demonstrated activity with manageable safety in platinum-resistant ovarian cancer patients, showing an overall response rate of 42.3% at 3.0 mg/kg and 58.8% at 2.0 mg/kg doses. The study highlights promising efficacy and safety in heavily pretreated patients, with a phase 3 trial ongoing for comparison with standard chemotherapy.